Nektar Therapeutics (NKTR) Short-term Investments (2010 - 2026)

Nektar Therapeutics' Short-term Investments history runs 17 years deep, the most recent figure standing at $419.0 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 133.13% year-over-year to $419.0 million in Q1 2026; TTM through Mar 2026 was $419.0 million, a 133.13% increase from a year earlier, with the FY2025 full-year figure at $230.6 million, up 9.32% from the prior year.
• Short-term Investments improved to $419.0 million in Q1 2026 per NKTR's latest filing, from $230.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $599.0 million in Q1 2022 and bottomed at $132.9 million in Q2 2025.
• The 5-year median for Short-term Investments is $268.3 million (2023), against an average of $318.4 million.
• Across the five-year window, Short-term Investments tumbled 49.18% in 2022 and soared 133.13% in 2026, its largest moves.
• Year by year, Short-term Investments stood at $416.8 million in 2022, then slumped by 35.61% to $268.3 million in 2023, then slipped by 21.38% to $211.0 million in 2024, then advanced by 9.32% to $230.6 million in 2025, then surged by 81.68% to $419.0 million in 2026.
• Per Business Quant, the three latest NKTR Short-term Investments figures stand at $419.0 million (Q1 2026), $230.6 million (Q4 2025), and $229.2 million (Q3 2025).